{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:03:54Z","timestamp":1791821034980,"version":"4.3.4"},"reference-count":24,"publisher":"Jaypee Brothers Medical Publishing","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.59556\/japi.74.1306","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:00:00Z","timestamp":1771830000000},"page":"e1-e7","source":"Crossref","is-referenced-by-count":3,"title":["A Prospective Real-world Study to Assess Safety, Tolerability, and Effectiveness of Imeglimin among People with Type 2 Diabetes Mellitus Who are Intolerant to Metformin (PRISM Study)"],"prefix":"10.59556","volume":"74","author":[{"given":"Prabhat Kumar","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan K","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhisekh","family":"Raha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Varshney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabh","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran Sharadchandra","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravinda","family":"Jagadeesha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sher Singh","family":"Dariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Saboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhakar Damodar","family":"Gokhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar Prafull","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Kumar B","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonika","family":"Lamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prahlad","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Pursnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumyaranjan","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchika","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"key":"key20260223065958_B1","first-page":"gfaf177.","volume-title":"Nephrology Dialysis Transplantation.","author":"Duncan","year":"2025."},{"issue":"(7):","key":"key20260223065958_B2","doi-asserted-by":"crossref","first-page":"474\u2013","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17).","volume":"11","author":"Anjana","year":"2023;","journal-title":"Lancet Diab Endocrinol"},{"key":"key20260223065958_B3","doi-asserted-by":"crossref","first-page":"2042018820980225.","DOI":"10.1177\/2042018820980225","article-title":"Should metformin remain the first-line therapy for treatment of type 2 diabetes?","volume":"12:","author":"Baker","year":"2021;","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"(3):","key":"key20260223065958_B4","doi-asserted-by":"crossref","first-page":"142\u2013","DOI":"10.5603\/cd.106925","article-title":"Imeglimin in metformin-intolerant patients with type 2 diabetes: a clinical advancement for real-world challenges.","volume":"14","author":"Chavda","year":"2025;","journal-title":"Clin Diabetol"},{"key":"key20260223065958_B5","doi-asserted-by":"crossref","first-page":"357.","DOI":"10.1186\/s13098-025-01922-2","article-title":"Imeglimin as an effective therapeutic approach in management of type 2 diabetes mellitus: an umbrella review and systematic review, meta-regression and meta-analysis.","volume":"17:","author":"Song","year":"2025;","journal-title":"Diabetol Metab Syndr"},{"issue":"(4):","key":"key20260223065958_B6","doi-asserted-by":"crossref","first-page":"537\u2013","DOI":"10.1089\/ars.2009.2531","article-title":"Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities.","volume":"12","author":"Sivitz","year":"2010;","journal-title":"Antioxid Redox Signal"},{"key":"key20260223065958_B7","doi-asserted-by":"crossref","first-page":"116755.","DOI":"10.1016\/j.biopha.2024.116755","article-title":"Exploring new mechanisms of imeglimin in diabetes treatment: amelioration of mitochondrial dysfunction.","volume":"175:","author":"Li","year":"2024;","journal-title":"Biomed Pharmacother"},{"issue":"(2):","key":"key20260223065958_B8","first-page":"6\u2013","article-title":"Mitochondrial dysfunction in type 2 diabetes mellitus imeglimin as a novel therapeutic approach.","volume":"25","author":"Kumar","year":"2025;","journal-title":"Asian J Diabetol"},{"issue":"(6):","key":"key20260223065958_B9","doi-asserted-by":"crossref","first-page":"e15\u2013","DOI":"10.59556\/japi.73.0938","article-title":"Imeglimin in type 2 diabetes mellitus: expert opinions and consensus in indian context.","volume":"73","author":"Seshadri","year":"2025;","journal-title":"J Assoc Physicians India"},{"issue":"(1):","key":"key20260223065958_B10","doi-asserted-by":"crossref","first-page":"357.","DOI":"10.1186\/s13098-025-01922-2","article-title":"Imeglimin as an effective therapeutic approach in management of type 2 diabetes mellitus: an umbrella review and systematic review, meta-regression and meta-analysis.","volume":"17","author":"Song","year":"2025;","journal-title":"Diabetol Metab Syndr"},{"issue":"(4):","key":"key20260223065958_B11","doi-asserted-by":"crossref","first-page":"952\u2013","DOI":"10.2337\/dc20-0763","article-title":"Efficacy and safety of imeglimin monotherapy versus placebo in japanese patients with type 2 diabetes (TIMES 1): a double-blind, randomized, placebo-controlled, parallel-group, multicenter phase 3 trial.","volume":"44","author":"Dubourg","year":"2021;","journal-title":"Diabetes Care"},{"issue":"(8):","key":"key20260223065958_B12","first-page":"e66322.","article-title":"Imeglimin for type 2 diabetes mellitus: its efficacy and insight into the potential benefit for renal and liver function.","volume":"16","author":"Uto","year":"2024;","journal-title":"Cureus"},{"issue":"(3):","key":"key20260223065958_B13","doi-asserted-by":"crossref","first-page":"154\u2013","DOI":"10.5603\/cd.104962","article-title":"Safety and efficacy of imeglimin in type 2 diabetes individuals with metformin intolerance: a case-control study.","volume":"14","author":"Agrawal","year":"2025;","journal-title":"Clin Diabetol"},{"issue":"(2):","key":"key20260223065958_B14","doi-asserted-by":"crossref","first-page":"102710.","DOI":"10.1016\/j.dsx.2023.102710","article-title":"Efficacy and safety of imeglimin in type 2 diabetes: a systematic review and meta-analysis of randomized placebo-controlled trials.","volume":"17","author":"Singh","year":"2023;","journal-title":"Diabetes Metab Syndr"},{"issue":"(11):","key":"key20260223065958_B15","doi-asserted-by":"crossref","first-page":"1246\u2013","DOI":"10.1111\/jdi.14070","article-title":"Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.","volume":"14","author":"Hagi","year":"2023;","journal-title":"J Diabetes Investig"},{"key":"key20260223065958_B16","doi-asserted-by":"crossref","first-page":"100164.","DOI":"10.1016\/j.deman.2023.100164","article-title":"The role of imeglimin in glycemic control, beta cell function and safety outcomes in patients with type 2 diabetes mellitus: a comprehensive meta-analysis.","volume":"12:","author":"Vinayagam","year":"2023;","journal-title":"Diabetes Epidemiol Manag"},{"issue":"(1):","key":"key20260223065958_B17","doi-asserted-by":"crossref","first-page":"89\u2013","DOI":"10.1080\/17446651.2023.2290488","article-title":"Different doses of imeglimin for management of type 2 diabetes mellitus: a systematic review, meta-analysis, and meta-regression of randomized clinical trials.","volume":"19","author":"Permana","year":"2024;","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"(6):","key":"key20260223065958_B18","doi-asserted-by":"crossref","first-page":"102323.","DOI":"10.1016\/j.dsx.2021.102323","article-title":"Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials.","volume":"15","author":"Abdelhaleem","year":"2021;","journal-title":"Diabetes Metab Syndr"},{"issue":"(3):","key":"key20260223065958_B19","doi-asserted-by":"crossref","first-page":"565\u2013","DOI":"10.2337\/dc12-0453","article-title":"The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.","volume":"36","author":"Fouqueray","year":"2013;","journal-title":"Diabetes Care"},{"issue":"(2):","key":"key20260223065958_B20","doi-asserted-by":"crossref","first-page":"182.","DOI":"10.4103\/jod.jod_208_24","article-title":"Evaluation of efficacy, safety, and tolerability of imeglimin hydrochloride SR tablets 1000 mg in participants with inadequately controlled type 2 diabetes mellitus: a phase III, randomized, double-blind, active-controlled, parallel group, multicenter clinical study from India.","volume":"16","author":"Kumthekar","year":"2025;","journal-title":"J Diabetol"},{"issue":"(4):","key":"key20260223065958_B21","doi-asserted-by":"crossref","first-page":"609\u2013","DOI":"10.1111\/dom.14613","article-title":"Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): a 52-week, open-label, multicentre phase 3 trial.","volume":"24","author":"Dubourg","year":"2022;","journal-title":"Diabetes Obes Metab"},{"issue":"(4):","key":"key20260223065958_B22","doi-asserted-by":"crossref","first-page":"645\u2013","DOI":"10.1007\/s13300-025-01693-z","article-title":"A multicenter, retrospective study to evaluate the effectiveness and safety of imeglimin in patients with type 2 diabetes mellitus in a real-world clinical setting (INDI-TIMES Study).","volume":"16","author":"Shaikh","year":"2025;","journal-title":"Diabetes Ther"},{"issue":"(3):","key":"key20260223065958_B23","first-page":"1334\u2013","article-title":"Safety and efficacy of imeglimin for type 2 diabetes in patients undergoing dialysis.","volume":"37","author":"Mima","year":"2023;","journal-title":"In Vivo (Athens Greece)"},{"issue":"(7):","key":"key20260223065958_B24","doi-asserted-by":"crossref","first-page":"807\u2013","DOI":"10.1002\/jcph.2218","article-title":"Pharmacokinetics and safety of imeglimin in Japanese patients with impaired renal function.","volume":"63","author":"Kitamura","year":"2023;","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:00:04Z","timestamp":1771830004000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-1-e1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.59556\/japi.74.1306"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1306","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}